After Moving of Regulatory T-Cell Therapy to the Clinic: Will We Need a New Tregs Source?

  • Elbadry M
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The last few decades, an intense interest has been developed in using regulatory T cells (Tregs) for immunotherapy by the biomedical community, depending on the facts that Tregs can modulate both innate and adaptive immunity. Recently, the therapeutic potential of Tregs has been moved to clinical practices in the field of autoimmune diseases and after allogeneic transplantation. Many clinical trials have involved Treg adoptive transfer to treat autoimmune diseases, solid organ transplantation, and hematopoietic stem cell transplantation (HSCT). The researchers have designed many strategies to isolate, preserve, expand, and infuse Tregs. However, the sources of Tregs cells remain one of many obstacles hindering Treg clinical applications. Here, we review current approaches have being explored for Treg expansion and the possible sources including induced pluripotent stem cells (iPSCs) in the perspective of clinical therapeutic protocols.

Cite

CITATION STYLE

APA

Elbadry, M. I. (2017). After Moving of Regulatory T-Cell Therapy to the Clinic: Will We Need a New Tregs Source? Hematology & Transfusion International Journal, 5(2). https://doi.org/10.15406/htij.2017.05.00117

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free